Ignite Creation Date:
2025-12-24 @ 11:42 PM
Ignite Modification Date:
2025-12-25 @ 9:34 PM
Study NCT ID:
NCT06393751
Status:
WITHDRAWN
Last Update Posted:
2025-06-03
First Post:
2024-04-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer
Sponsor:
National Cancer Institute (NCI)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-10-31
Start Date Type:
ESTIMATED
Primary Completion Date:
2028-02-09
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-02-09
Completion Date Type:
ESTIMATED
First Submit Date:
2024-04-30
First Submit QC Date:
None
Study First Post Date:
2024-05-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-06-02
Last Update Post Date:
2025-06-03
Last Update Post Date Type:
ACTUAL